Abstract: Described herein are chemokine-binding domains of THAP-family polypeptides and pharmaceutical compositions which include a polypeptide comprising a chemokine-binding domain of a THAP-family polypeptide. Also disclosed are methods of binding chemokines, inhibiting the activity of chemokines, detecting chemokines, and reducing the symptoms associated with a chemokine mediated or influenced condition by contacting the chemokine with an agent that includes a polypeptide comprising a chemokine binding domain of a THAP-family polypeptide.

Abstract: The present invention relates to a pharmaceutical composition comprising as active substances: at least one compound of the following general formula (I): and at least one compound of the following general formula (V): especially for its use in the prevention or treatment of pain.

Abstract: The invention relates to genes and proteins of the THAP (THanatos (death)-Associated Protein) family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to the Par4 protein and SLC chemokine pathways, including the interaction of Par4 and SLC with THAP family proteins, and the recruitment and localization of Par4 to PML nuclear bodies.

Abstract: A circuit for providing a bandgap voltage. The circuit includes a classic bandgap reference voltage generation circuit including first end second serially connected transistors acting as a current mirror to another portion of the classical bandgap reference circuit and being coupled between a supply voltage Vdd and an output resistor. The circuit also includes a current trimming circuit coupled in parallel with the classical bandgap reference generation circuit including a fixed element portion including a plurality of transistors and a switch portion including a plurality of switches. Each of the plurality of transistors is coupled to the supply voltage Vdd and to a one of the plurality of switches and each switch includes a fuse.

Abstract: The invention relates to genes and proteins of the THAP (THanatos (death)-Associated Protein) family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to the Par4 protein and SLC chemokine pathways, including the interaction of Par4 and SLC with THAP family proteins, and the recruitment and localization of Par4 to PML nuclear bodies.

Abstract: The present invention relates to the use of at least one compound of formula (I) below: or of its pharmaceutically acceptable salts, in the preparation of a medicament for the prevention or treatment of cerebral oedemas.

Abstract: This invention relates to the use of at least one compound of the following formula (I): or its pharmaceutically acceptable salts, for the preparation of a medicinal compound having neuroprotective activity intended to prevent or treat neurone deteriorations.

Abstract: Aspects of the present invention relate to NF-HEV nuclear factor genes and polypeptides. Other aspects related to the use of NF-HEV nuclear factor genes and polypeptides. Other aspects related to the use of NF-HEV nuclear factor polynucleotides and polypeptides expressed in endothelial cells from chronically inflamed tissues, particularly in high endothelial venules endothelial cells (HEVECs) and endothelial cells from HEV-like vessels and small blood vessels, in connection with rheumatoid arthritis and Crohn's disease. Aspects of the invention also relates to drug screening assays for identifying compounds capable of modulating NF-HEV activity, wherein such compounds can be used in inhibiting or preventing chronic inflammation.

Abstract: The present invention relates to the use of at least one compound of formula (I) below: or of its pharmaceutically acceptable salts, in the preparation of a medicament for the prevention or treatment of cerebral oedemas.

Abstract: Among the methods and compositions described herein are methods of ameliorating one or more symptoms associated with a chemokine-mediated or influenced condition by providing to a subject an agent that includes a polypeptide comprising a chemokine binding domain of a THAP-family polypeptide.

Abstract: The present invention relates to the use of at least one compound of formula (I) below: or at least one of the pharmaceutically acceptable salts thereof, for the preparation of a medicament intended for the prevention or for the treatment of cerebral oedemas.

Abstract: Described herein are chemokine-binding domains of THAP-family polypeptides and pharmaceutical compositions which include a polypeptide comprising a chemokine-binding domain of a THAP-family polypeptide. Also disclosed are methods of binding chemokines, inhibiting the activity of chemokines, detecting chemokines, and reducing the symptoms associated with a chemokine mediated or influenced condition by contacting the chemokine with an agent that includes a polypeptide comprising a chemokine binding domain of a THAP-family polypeptide.

Abstract: Described herein are chemokine-binding domains of THAP-family polypeptides and pharmaceutical compositions which include a polypeptide comprising a chemokine-binding domain of a THAP-family polypeptide. Also disclosed are methods of binding chemokines, inhibiting the activity of chemokines, detecting chemokines, and reducing the symptoms associated with a chemokine mediated or influenced condition by contacting the chemokine with an agent that includes a polypeptide comprising a chemokine binding domain of a THAP-family polypeptide.

Abstract: Described herein are chemokine-binding domains of THAP-family polypeptides and pharmaceutical compositions which include a polypeptide comprising a chemokine-binding domain of a THAP-family polypeptide. Also disclosed are methods of binding chemokines, inhibiting the activity of chemokines, detecting chemokines, and reducing the symptoms associated with a chemokine mediated or influenced condition by contacting the chemokine with an agent that includes a polypeptide comprising a chemokine binding domain of a THAP-family polypeptide.

Abstract: A method and apparatus for a continuous coating of a part may include providing a separation layer made of a material that is weaker than the material of the coating to be made. The part may be placed on one or more supports, the supports coated with the separation layer. A continuity layer of a component material of the coating to be made is interposed between the part and the or each support, at least in vicinity of the or each support zone. The coating is formed by chemical vapor infiltration or deposition, and the part is then separated from the or each support by rupture within the separation layer, the continuity of the coating of the part in the or each support zone being provided by the portion of the coating that comes from the continuity layer that remains in place on the part.

Abstract: There is disclosed an improved differential amplifier (20) having a feedback loop that generates an amplified output signal (Vout) from an input signal (Vin) supplied by a preceding stage. It comprises an input matching circuit (11) connected to said preceding stage, a buffer (22) and an amplification section (12) connected in series in the direct amplification line, a first amplifier (16), a RC network (17?) and a second amplifier (23) connected in series in a parallel loop between the outputs and the inputs of the amplification section that generate the feedback signal. The role of said buffer and second amplifier associated in a dedicated direct and feedback signal combining block (21) is to respectively isolate the input signal and the feedback signal from the summing nodes (A?,B?) at the amplification section inputs. As a result, the summation of the input signal and the feedback signal is improved, the DC component of the output signal is filtered out in order to significantly reduce the DC offset.

Abstract: There is disclosed an improved 2-stage large bandwidth amplifier (20) comprised of two stages formed by first and second bipolar transistors (Q1,Q2) configured in common emitter that are connected in series with their emitters connected to a first supply voltage (Gnd). The input signal (Vin) is applied to the base of said first transistor via an input terminal (11), while the output signal (Vout) is available at an output terminal (12) connected to the collector of said second transistor. A parallel feedback structure (13?) is provided. It consists, in a first branch, of two diodes (D1,D2) in series connected between a second supply voltage (Vcc) and the collector of the second bipolar transistor, and in another branch of a third bipolar transistor (Q3) configured in emitter follower with a resistor (Rf) in the emitter. The base and the collector of said third bipolar transistor are respectively connected to the common node of said diodes and to said second supply voltage.

Abstract: There is disclosed an improved 2-stage large bandwidth amplifier (20) comprised of two stages formed by first and second bipolar transistors (Q1,Q2) configured in common emitter that are connected in series with their emitters connected to a first supply voltage (Gnd). The input signal (Vin) is applied to the base of said first transistor via an input terminal (11), while the output signal (Vout) is available at an output terminal (12) connected to the collector of said second transistor. A parallel feedback structure (13′) is provided. It consists, in a first branch, of two diodes (D1,D2) in series connected between a second supply voltage (Vcc) and the collector of the second bipolar transistor, and in another branch of a third bipolar transistor (Q3) configured in emitter follower with a resistor (Rf) in the emitter. The base and the collector of said third bipolar transistor are respectively connected to the common node of said diodes and to said second supply voltage.

Abstract: The invention relates to genes and proteins of the THAP family comprising a THAP domain, and their use in diagnostics, treatment of disease, and in the identification of molecules for the treatment of disease. The invention also relates to uses of THAP-type chemokine-binding agents, such as THAP-family proteins, as a nuclear receptors for a chemokines and to methods for the modulation (stimulation or inhibition) of transcription, cell proliferation and cell differentiation as well as methods for identifying for compounds which modulate THAP-chemokine interactions.

Abstract: A part (10) on which a continuous coating is to be formed is put into place on one or more supports provided with a separation layer (26) made of a material that is weaker than the material of the coating to be made. A continuity layer (24) of a component material of the coating to be made is interposed between the part and the or each support, at least in vicinity of the or each support zone. The coating (12) is formed by chemical vapor infiltration or deposition, and the part is then separated from the or each support by rupture within the separation layer (26), the continuity of the coating of the part in the or each support zone being provided by the portion of the coating that comes from the continuity layer (24) that remains in place on the part.